Stifel Nicolaus Downgrades Salix Pharmaceuticals To Hold

Analysts at Stifel Nicolaus downgraded Salix Pharmaceuticals SLXP from Buy to Hold and removed the price target of $189. Salix Pharma shares have jumped 64.94% over the past 52 weeks, while the S&P 500 index has gained 14.72% in the same period. Salix Pharmaceuticals' shares dipped 36.95% to $87.36 in pre-market trading.